Helus Pharma Strengthens Leadership Ahead of Commercialization Push
Event summary
- Helus Pharma appointed Regina Donohue as Chief People Officer, bringing experience in scaling life sciences companies from clinical to commercial stages.
- Suresh Durgam, M.D., joined the Scientific Advisory Board, known for his role in securing FDA approvals for CAPLYTA® (lumateperone).
- Donohue previously led HR at Intra-Cellular Therapies during its transition to a commercial-stage organization with 1,000+ employees.
- Durgam has over two decades of CNS drug-development experience, including leadership roles at Allergan, Forest Laboratories, and Solvay Pharmaceuticals.
The big picture
Helus Pharma is positioning itself for potential commercialization with key leadership appointments. The additions of Regina Donohue and Suresh Durgam, M.D., reflect a strategic focus on scaling operations and strengthening scientific guidance. This move aligns with broader industry trends of biotech companies fortifying their executive teams ahead of major regulatory and commercial milestones.
What we're watching
- Commercialization Readiness
- How Regina Donohue's experience will shape Helus Pharma's transition from clinical to commercial stages.
- Regulatory Strategy
- Whether Suresh Durgam's expertise can accelerate FDA approvals for Helus Pharma's pipeline.
- Organizational Scale
- The pace at which Helus Pharma can grow its workforce and infrastructure to support commercialization.
Related topics